Watch More Highlights
Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses key insights for advanced practitioners from the DREAMM-2 study, which detailed the self-reported experiences of patients with relapsed or refractory multiple myeloma who had treatment-related side effects from belantamab mafodotin (Abstract 3248).